126 related articles for article (PubMed ID: 11249665)
1. RNA-polymerase III-driven expression cassettes in human gene therapy.
Medina MF; Joshi S
Curr Opin Mol Ther; 1999 Oct; 1(5):580-94. PubMed ID: 11249665
[TBL] [Abstract][Full Text] [Related]
2. Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study.
Ilves H; Barske C; Junker U; Böhnlein E; Veres G
Gene; 1996 Jun; 171(2):203-8. PubMed ID: 8666273
[TBL] [Abstract][Full Text] [Related]
3. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.
Thompson JD; Ayers DF; Malmstrom TA; McKenzie TL; Ganousis L; Chowrira BM; Couture L; Stinchcomb DT
Nucleic Acids Res; 1995 Jun; 23(12):2259-68. PubMed ID: 7610054
[TBL] [Abstract][Full Text] [Related]
4. Utility of Epstein-Barr virus-encoded small RNA promoters for driving the expression of fusion transcripts harboring short hairpin RNAs.
Choy EY; Kok KH; Tsao SW; Jin DY
Gene Ther; 2008 Feb; 15(3):191-202. PubMed ID: 17972920
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.
Li MJ; Bauer G; Michienzi A; Yee JK; Lee NS; Kim J; Li S; Castanotto D; Zaia J; Rossi JJ
Mol Ther; 2003 Aug; 8(2):196-206. PubMed ID: 12907142
[TBL] [Abstract][Full Text] [Related]
6. Localized expression of small RNA inhibitors in human cells.
Paul CP; Good PD; Li SX; Kleihauer A; Rossi JJ; Engelke DR
Mol Ther; 2003 Feb; 7(2):237-47. PubMed ID: 12597912
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters.
Lo HL; Chang T; Yam P; Marcovecchio PM; Li S; Zaia JA; Yee JK
Gene Ther; 2007 Nov; 14(21):1503-12. PubMed ID: 17805304
[TBL] [Abstract][Full Text] [Related]
8. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization.
Bertrand E; Castanotto D; Zhou C; Carbonnelle C; Lee NS; Good P; Chatterjee S; Grange T; Pictet R; Kohn D; Engelke D; Rossi JJ
RNA; 1997 Jan; 3(1):75-88. PubMed ID: 8990401
[TBL] [Abstract][Full Text] [Related]
9. Expression of short hairpin RNAs using the compact architecture of retroviral microRNA genes.
Burke JM; Kincaid RP; Aloisio F; Welch N; Sullivan CS
Nucleic Acids Res; 2017 Sep; 45(17):e154. PubMed ID: 28973449
[TBL] [Abstract][Full Text] [Related]
10. Interference between effector RNAs expressed from conventional dual-function anti-HIV retroviral vectors can be circumvented using dual-effector-cassette retroviral vectors.
Peng H; Callison D; Li P; Burrell CJ
Hum Gene Ther; 1999 Feb; 10(3):449-62. PubMed ID: 10048397
[TBL] [Abstract][Full Text] [Related]
11. Polycistronic expression of interfering RNAs from RNA polymerase III promoters.
Steel LF; Sanghvi VR
Methods Mol Biol; 2012; 815():347-59. PubMed ID: 22131004
[TBL] [Abstract][Full Text] [Related]
12. Identification and comparison of the porcine H1, U6, and 7SK RNA polymerase III promoters for short hairpin RNA expression.
Yin HC; Chen XY; Wang W; Meng QW
Mamm Genome; 2020 Apr; 31(3-4):110-116. PubMed ID: 32318815
[TBL] [Abstract][Full Text] [Related]
13. Subcellular distribution of small interfering RNA: directed delivery through RNA polymerase III expression cassettes and localization by in situ hybridization.
Paul CP
Methods Enzymol; 2005; 392():125-45. PubMed ID: 15644179
[TBL] [Abstract][Full Text] [Related]
14. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
Kaszubiak A; Holm PS; Lage H
Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700
[TBL] [Abstract][Full Text] [Related]
16. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
Li MJ; Kim J; Li S; Zaia J; Yee JK; Anderson J; Akkina R; Rossi JJ
Mol Ther; 2005 Nov; 12(5):900-9. PubMed ID: 16115802
[TBL] [Abstract][Full Text] [Related]
17. Use of a nonviral vector to express a chimeric tRNA-ribozyme against lymphocytic choriomeningitis virus: cytoplasmic accumulation of a catalytically competent transcript but minimal antiviral effect.
Gebhard JR; Perry CM; Mahadeviah S; Whitton JL
Antisense Nucleic Acid Drug Dev; 1997 Feb; 7(1):3-11. PubMed ID: 9055033
[TBL] [Abstract][Full Text] [Related]
18. Expression of small, therapeutic RNAs in human cell nuclei.
Good PD; Krikos AJ; Li SX; Bertrand E; Lee NS; Giver L; Ellington A; Zaia JA; Rossi JJ; Engelke DR
Gene Ther; 1997 Jan; 4(1):45-54. PubMed ID: 9068795
[TBL] [Abstract][Full Text] [Related]
19. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.
Mautino MR; Morgan RA
Hum Gene Ther; 2002 Jun; 13(9):1027-37. PubMed ID: 12067436
[TBL] [Abstract][Full Text] [Related]
20. Retroviral delivery and anti-HIV testing of hammerhead ribozymes.
Cagnon L; Rossi J
Methods Mol Biol; 1997; 74():451-7. PubMed ID: 9204460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
